Evidence map›Paper›PMID 32699527›Full record

ArticleCancer cell international2020

EO771, the first luminal B mammary cancer cell line from C57BL/6 mice.

Augustin Le Naour, Yvonne Koffi, Mariane Diab, Delphine Le Guennec, Stéphanie Rougé, Sahar Aldekwer, Nicolas Goncalves-Mendes, Jérémie Talvas, Marie-Chantal Farges, Florence Caldefie-Chezet and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. SPRED2 Negatively Regulates CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Intratumoral TScience immunology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Augustin Le NaourHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.ORCID 0000-0003-1790-4543
Yvonne KoffiHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Mariane DiabHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Delphine Le GuennecHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Stéphanie RougéHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Sahar AldekwerHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Nicolas Goncalves-MendesHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Jérémie TalvasHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Marie-Chantal FargesHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Florence Caldefie-ChezetHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Marie-Paule VassonHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Adrien RossaryHuman Nutrition Unit, ECREIN team, UMR 1019, University of Clermont Auvergne, INRAE, CRNH-Auvergne, TSA 50400, 28 place Henri Dunant, 63000 Clermont-Ferrand Cedex 1, France.
Université Clermont Auvergne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite decades of therapeutic trials, effective diagnosis, many drugs available and numerous studies on breast cancer, it remains the deadliest cancer in women. In order to choose the most appropriate treatment and to understand the prognosis of the patients, breast cancer is divided into different subtypes using a molecular classification. Just as there remains a need to discover new effective therapies, models to test them are also required.

methodsThe EO771 (also named E0771 or EO 771) murine mammary cancer cell line was originally isolated from a spontaneous tumour in C57BL/6 mouse. Although frequently used, this cell line remains poorly characterized. Therefore, the EO771 phenotype was investigated. The phenotype was compared to that of MCF-7 cells, known to be of luminal A subtype and to express estrogen receptors, as well as MDA-MB-231 cells, which are triple negative. Their sensitivity to hormonal treatment was evaluated by viability tests.

resultsThe EO771 were estrogen receptor α negative, estrogen receptor β positive, progesterone receptor positive and ErbB2 positive. This phenotype was associated with a sensitivity to anti-estrogen treatments such as tamoxifen, 4-hydroxy-tamoxifen, endoxifen and fulvestrant.

conclusionsOn account of the numerous results published with the EO771 cell line, it is important to know its classification, to facilitate comparisons with corresponding types of tumours in patients. Transcriptomic and protein analysis of the EO771 cell line classified it within the luminal B subtype. Luminal B cancers correspond to one of the subtypes most frequently encountered in patients and associated with a poor prognosis.

Indexed as

Antineoplastic agentsBreast neoplasmsestrogenHormonalinbred C57BLMiceReceptorsTamoxifen

Identifiers

PMID32699527
PMCPMC7372867
OpenAlexW3043753157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.